Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cytotoxic T-lymphocyte-associated protein 4-immunoglobulin
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Cytotoxic T-lymphocyte-associated protein 4-immunoglobulin (CTLA-4Ig) is a soluble recombinant fusion protein consisting of the extracellular domain of human CTLA-4 (CD152) fused to the Fc portion of human immunoglobulin G1 (IgG1). CTLA-4Ig acts as a selective co-stimulation modulator by binding with high affinity to CD80 (B7-1) and CD86 (B7-2) on antigen-presenting cells (APCs). This binding competitively blocks the interaction of CD80/CD86 with CD28 on T cells, thereby preventing the second co-stimulatory signal required for full T-cell activation, proliferation, and cytokine production. CTLA-4Ig is widely used as an immunosuppressive agent to prevent transplant rejection (e.g., belatacept in kidney transplantation) and to treat autoimmune diseases such as rheumatoid arthritis and juvenile idiopathic arthritis (e.g., abatacept).
- Brand names
- NulojixOrencia
- Other names
- CTLA-4-IgCTLA4-IgCTLA 4-IgCTLA-4IgCTLA4IgCTLA 4IgCTLA4-immunoglobulinCTLA-4-immunoglobulinCTLA 4-immunoglobulincytotoxic T-lymphocyte-associated antigen 4-immunoglobulin
02
Targets
CD28 (Cluster of Differentiation 28)CD80 (T-lymphocyte activation antigen CD80)CD86 (T-lymphocyte activation antigen CD86)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)NeuraminidaseFcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)
Beyond the preview
Go deeper on cytotoxic T-lymphocyte-associated protein 4-immunoglobulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cytotoxic T-lymphocyte-associated protein 4-immunoglobulin.